• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine. CROSS-REACTIVE ANTIBODIES IN MIDDLE-AGED AND ELDERLY VOLUNTEERS AFTER MF59-ADJUVANTED SUBUNIT TRIVALENT INFLUENZA VACCINE AGAINST B VIRUSES O

Giuseppe

Emeritus
Vaccine. 2009 Apr 30. [Epub ahead of print]

CROSS-REACTIVE ANTIBODIES IN MIDDLE-AGED AND ELDERLY VOLUNTEERS AFTER MF59-ADJUVANTED SUBUNIT TRIVALENT INFLUENZA VACCINE AGAINST B VIRUSES OF THE B/VICTORIA OR B/YAMAGATA LINEAGES.

Camilloni B, Neri M, Lepri E, Iorio AM. - Department of Medical and Surgical Specialties and Public Health, University of Perugia, Via del Giochetto, 06126 Perugia, Italy.


This study evaluated whether MF59-adjuvanted subunit trivalent influenza vaccine for the 2003/04 winter season (A/Moscow/10/99, H3N2; A/New Caledonia/20/99, H1N1; B/Hong Kong/330/01) would confer protection against mismatched and frequently co-circulating variants of influenza B/Victoria- and B/Yamagata-like virus strains.
Haemagglutination inhibiting (HI) antibodies were measured in middle-aged and elderly volunteers against the homologous B/Victoria-like vaccine strain (B/Hong Kong/330/01) and against mismatched B/Victoria-like (B/Malaysia/2506/04) and B/Yamagata-like (B/Singapore/379/99 and B/Shanghai/361/02) strains.
Immunization induced significant increases in the amounts of HI antibodies against all influenza B strains under investigation.
However, the responses against the heterologous B/Shanghai/361/02 virus did not reach the desirable values of seroprotection.
An age-dependent decline of the responses was found for B/Victoria-like antigens, but not for B/Yamagata-like strains.
Although further studies are needed, our data support the recommendation of including influenza B viruses of the B/Victoria and B/Yamagata lineages in the future influenza vaccine preparations.

PMID: 19410623 [PubMed - as supplied by publisher]
-
------
 
Back
Top